INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/018506

	CATION OF SUBJECT MATTER ONE OF SUBJECT MATTER CO7K16/28, C12N15/11, C12N5/	06, A61K39/395		
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SE	ARCHED			
Minimum docur	mentation searched (classification system followed by cl	lassification symbols)		
Int.Cl ⁷ C07K16/28, C12N15/11, C12N5/06, A61K39/395				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) JSTPlus, WPI (DIALOG), BIOSIS (DIALOG), PUBMED				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where ap		Relevant to claim No.	
X	WO 02/033072 A1 (Chugai Phar Co., Ltd.),	maceutical	1-4	
	25 April, 2002 (25.04.02),			
	& AU 200210917 A & EP	1327680 A1		
	& KR 2003055274 A & JP			
	& CN 1469925 A & US Page 4, line 19 to page 5, li	2004/0091475 A1		
	line 26 to page 13; pages 27,			
х	WO 02/033073 Al (Chugai Phar Co., Ltd.),	maceutical	1-4	
i	25 April, 2002 (25.04.02),	1207601 71		
	& AU 200210918 A & EP & KR 2003055273 A & JP			
		2004/0242847 A1		
	Page 4, line 27 to page 6, li	ne 24; page 15,		
	line 2 to page 16, line 28; p	page 31; Fig. 34		
Further do	cuments are listed in the continuation of Box C.	See patent family annex.		
"A" document d	gories of cited documents: efining the general state of the art which is not considered icular relevance	"T" later document published after the inte date and not in conflict with the applica the principle or theory underlying the ir	tion but cited to understand	
"E" earlier appli	cation or patent but published on or after the international	"X" document of particular relevance; the c considered novel or cannot be consid		
cited to esta	thich may throw doubts on priority claim(s) or which is blish the publication date of another citation or other on (as specified)	step when the document is taken alone "Y" document of particular relevance; the cl		
"O" document re	ferring to an oral disclosure, use, exhibition or other means	considered to involve an inventive s combined with one or more other such	documents, such combination	
"P" document pu priority date	blished prior to the international filing date but later than the claimed	being obvious to a person skilled in the "&" document member of the same patent for		
Date of the actual completion of the international search 04 March, 2005 (04.03.05)		Date of mailing of the international search report 22 March, 2005 (22.03.05)		
Name and mailin	g address of the ISA/	Authorized officer		
Japanese Patent Office				
Facsimile No.				
	0 (second sheet) (January 2004)			

COPY SUBMITTED IN IDS

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/018506

Box No	o. II Observations where certain claims were found unsearchable (Continu	ation of item 2 of first sheet)	
This into	ternational search report has not been established in respect of certain claims under Ar Claims Nos.: because they relate to subject matter not required to be searched by this Authority,		
2.	Claims Nos.: because they relate to parts of the international application that do not comply with extent that no meaningful international search can be carried out, specifically:	he prescribed requirements to such an	
3. [Claims Nos.: because they are dependent claims and are not drafted in accordance with the seco	nd and third sentences of Rule 6.4(a).	
Box No.	Observations where unity of invention is lacking (Continuation of item	a 3 of first sheet)	
	temational Searching Authority found multiple inventions in this international applic See extra sheet)		
1	As all required additional search fees were timely paid by the applicant, this internat claims.	ional search report covers all searchable	
	As all searchable claims could be searched without effort justifying an additional fee, the any additional fee.	is Authority did not invite payment of	
	As only some of the required additional search fees were timely paid by the applicant only those claims for which fees were paid, specifically claims Nos.:	t, this international search report covers	
4. X No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: Claims 1 to 4.			
Remark	k on Protest The additional search fees were accompanied by the app	olicant's protest.	
	No protest accompanied the payment of additional search	h fees.	

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No. PCT/JP2004/018506

Continuation of Box No.III of continuation of first sheet (2)

The matter common mutually or totally to claims 1 to 4, claims 5 to 7, claim 8, claim 9, claim 10, claims 11 to 12, claims 13 to 15, the part of claim 16 relating to a combination of sequences of individual SEQ ID NOS, the part of claim 17 relating to a combination of sequences of individual SEQ ID NOS, claim 19, claim 20, the part of claim 21 relating to a combination of sequences of individual SEQ ID NOS, the part of claim 23 relating to a combination of sequences of individual SEQ ID NOS, the part of claim 24 relating to a combination of sequences of individual SEQ ID NOS, the part of claim 26 relating to a combination of sequences of individual SEQ ID NOS, the part of claim 27 relating to a combination of sequences of individual SEQ ID NOS, the part of claim 29 relating to a combination of sequences of individual SEQ ID NOS and claim 32 resides in being an antibody capable of binding to a TPO receptor.

The antibody as used in the present application involves degraded antibodies including antibody fragments. As reported in documents 1 to 3, antibodies or antibody fragments capable of binding to a TPO receptor and those having agonistic activities among them are publicly known.

Therefore, being an antibody capable of binding to a TPO receptor cannot be considered as a special technical feature in the meaning within the second sentence of PCT Rule 13.2. Since there is no common matter seemingly being a special technical feature in the meaning within the second sentence of PCT Rule 13.2, no technical relationship in the meaning within PCT Rule 13 can be found out among these invention groups differing from each other.

Such being the case, the inventions according to claims 1 to 38 are considered not as a group of inventions so linked as to form a single general inventive concept but as invention groups having 62 inventions respectively relating to 62 different antibodies. Therefore, it is obvious that these claims do not comply with the requirement of unity of invention.

Document 1: International Publication No.99/10494 pamphlet Document 2: International Publication No.02/33072 pamphlet Document 3: International Publication No.02/33703 pamphlet